DME, also known as 3,4-dimethoxy-ò-hydroxyphenethylamine or as ò-hydroxy-3,4-DMPEA, is a psychoactive drug of the phenethylamine and BOx families. It is the ò-hydroxy derivative of 3,4-dimethoxyphenethylamine (3,4-DMPEA or DMPEA), which is an analogue of mescaline (3,4,5-TMPEA or TMPEA).
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists DME's dose as greater than 115mg orally and its duration as unknown. At a dose of 115mg orally, its effects included faint nausea and possible alertness, but described as "substantially no effects".
The chemical synthesis of DME has been described.
Analogues of DME (ò-hydroxy-3,4-DMPEA) include BOH (ò-methoxy-MDPEA) and BOM (ò-methoxymescaline; ò-methoxy-3,4,5-TMPEA), among others.
DME was first described in the scientific literature by Alexander Shulgin and colleagues in 1969. It was subsequently described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.